Tetracaine hydrochloride, CAS 136-47-0, is a para-aminobenzoic acid ester local anesthetic supplied as a white to off-white crystalline powder for veterinary compounding into tablets, injections, capsules, powders, granules, premixes and solutions. The hydrochloride salt has a molecular weight of 300.83 g/mol, a tertiary amine pKa near 8.5, and a free-base log P near 3.7; these physicochemical features produce a slower onset but longer local anesthetic effect than procaine hydrochloride. Tetracaine blocks voltage-gated sodium channels by stabilizing the inactive state of the channel, raising the threshold for action potential propagation. The ester linkage is hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol derivatives; this metabolic route is faster than hepatic amide cleavage but can generate para-aminobenzoic acid-related hypersensitivity reactions. The veterinary-grade API is a high-potency local anesthetic and requires enclosed transfer, local exhaust ventilation, and dust-control measures during dispensing. It is not supplied as a sterile API; the finished dosage form must establish sterility, pyrogenicity, and species-specific safety before administration.

How Does Veterinary-Grade Tetracaine Hydrochloride Differ from Human Compendial API?

The molecular identity and compendial acceptance criteria for veterinary-grade tetracaine HCl generally align with the USP Tetracaine Hydrochloride monograph and the corresponding Ph. Eur. monograph. The release specification includes appearance, identification, assay, related substances, residual solvents, elemental impurities, and microbial quality for the intended route. The practical distinction is not a different chemical entity but the supply-chain documentation, veterinary GMP audit trail, and packaging grade. Veterinary-grade material may be released in non-sterile, animal-origin-free packaging, with endotoxin data provided only when requested for injectable compounding. 21 CFR 211.42 design and construction requirements are not automatically applicable to a non-sterile veterinary API producer, but sterile injectable processing must meet aseptic process controls consistent with 21 CFR 211.113 or EU GMP Annex 1. Purchasers should obtain a certificate of analysis, a transmissible spongiform encephalopathy declaration, a residual solvent report, and elemental impurity data. The numerical values in the specification matrix below are supplier acceptance limits and must be verified against the monograph of the intended regulatory region.

Compared with lidocaine hydrochloride, tetracaine HCl is ester-type rather than amide-type, more lipophilic, slower in onset, and longer in duration. That substitution cannot be treated as iso-equivalent when adjusting doses in multispecies compounding. Compared with procaine hydrochloride, tetracaine is substantially more potent and more likely to produce cardiovascular and neurological toxicity if dosing is extrapolated without species-specific calculation. Residual solvents are typically limited to Class 3 alcohols or ethers, and halogenated solvents are excluded. Because the API monograph does not include a bacterial endotoxin limit for nonsterile routes, endotoxin control is a finished-product specification selected by the compounder based on route and dose.

Wet Granulation and Direct Compression Windows for Tetracaine Hydrochloride Powders

Tetracaine HCl is typically milled before solid-dosage compounding because unmicronized crystals exhibit poor flow and agglomeration above 60% relative humidity. A low-dose premix containing 0.5–2.0% w/w tetracaine HCl on lactose monohydrate can be prepared in a 600 L V-blender at 25 rpm for 20 min; blend uniformity RSD values below 5% are achievable when the API is pre-sieved through a 250 µm screen and the blender fill volume is ≤ 70% of nominal capacity. At API content below 0.5% w/w, direct blending is more prone to segregation; a geometric pre-dilution with an intermediate 5% w/w API-lactose mixture is recommended before final blending. Content uniformity in tablets should be evaluated per USP <905>; capsules should meet the same acceptance value ≤ 15 unless a compendial alternative is justified.

For wet granulation in a high-shear mixer, the API is dry-mixed with lactose monohydrate, microcrystalline cellulose, and sodium starch glycolate at impeller 150 rpm and chopper 3,000 rpm for 5 min; purified water is added at 4.0 kg/min to a target granulation moisture of 8–10% w/w. Drying in a fluid-bed at inlet air 60 °C to loss-on-drying 1.5–2.5% produces granules with bulk density 0.45–0.55 g/mL. The hydrochloride salt should not be granulated with citric acid or tartaric acid at high moisture because local pH below 2.0 accelerates ester hydrolysis. The wet mass should not be held longer than 4 h before drying. Residual moisture above 2.0% in the final blend reduces chemical stability and increases tablet sticking on steel tooling. Direct compression requires a pre-milled grade with D90 ≤ 25 µm; tablet compression with 8–25 kN force on a rotary press monitored by in-process hardness 40–80 N generally yields friability ≤ 0.8% when magnesium stearate is limited to 0.25–0.50% w/w. Higher magnesium stearate levels reduce tablet strength and retard dissolution because the hydrophobic lubricant coats the API particles.

For capsules, the granular material is filled with dosator or tamping-pin encapsulation equipment. Because tetracaine HCl is hygroscopic, filling operations above 55% RH increase sticking and weight variability. Pre-sieving with 0.5% colloidal silicon dioxide and 0.5% magnesium stearate reduces hopper bridging in automatic capsule machines. Powders for oral suspension are compounded with suspending agents such as xanthan gum 0.2–0.5% and preserved with potassium sorbate 0.1% when packaged in multi-dose containers. The bitter taste is masked in granules by wet-massing with hydroxypropyl methylcellulose 3–5% and sucralose, but the high water solubility of tetracaine HCl, approximately 50 mg/mL at 20 °C, causes release during saliva contact; acid-resistant film coating is therefore more effective than simple sugar coating for taste-masked oral granules. Premix for medicated feed is typically prepared as a 1:100 dilution in lactose or corn starch under low-humidity conditions; carrier particle size distribution should be matched to the feed-mill mixer to avoid segregation. Effervescent vehicles containing citric acid and sodium bicarbonate are unsuitable because low local pH and moisture migration accelerate ester hydrolysis. Compounded powders packaged in low-density polyethylene bags at 25 °C/60% RH are usually assigned a provisional retest date of 12 months; granule blends containing free water above 2% can exhibit ester hydrolysis within weeks.

When Tetracaine Hydrochloride Replaces Lidocaine in Compounded Veterinary Injectables

The substitution is not iso-equivalent because tetracaine is commonly described as four to ten times more potent than lidocaine in infiltrative block models, although the exact ratio varies by species, injection site, and nerve diameter. Tetracaine has a slower onset because its pKa is 8.5; the un-ionized fraction at tissue pH 7.4 is approximately 7–8%, compared with approximately 25% un-ionized lidocaine at pKa 7.9. The ester linkage produces a lower risk of hepatic metabolite accumulation than lidocaine’s oxidative N-dealkylation, but a higher risk of allergic sensitization due to para-aminobenzoic acid formation. In veterinary practice, tetracaine solutions are compounded at 0.5–2.0% w/v for infiltration, nerve block, or topical mucosal use. Injectable solutions must be preservative-free for spinal or epidural use and made isotonic with sodium chloride 0.9% w/v. Dextrose-containing or sodium bicarbonate-containing vehicles are not recommended because they accelerate hydrolytic degradation.

For small-volume injectables, aseptic filtration through a 0.22 µm PVDF membrane is preferred to terminal steam sterilization. The ester bond undergoes pH- and temperature-dependent hydrolysis; degradation rate increases rapidly above 70 °C. Autoclaving at 121 °C for 15 min can reduce assay by more than 5% at pH 6.0, although the loss is lower at pH 4.5. Terminal moist-heat sterilization is therefore selected only after confirming pH-controlled stability in the specific container-closure system. Multi-dose vials require antimicrobial effectiveness testing per USP <51> or Ph. Eur. 5.1.3; phenolic preservatives can interact with filter membranes and should be compatibility-tested. Solutions should be protected from light and stored at 2–8 °C if held longer than 24 h before sterilization. The molecule undergoes photolytic degradation that produces N-oxide and para-aminobenzoic acid-related impurities; amber glass is the preferred primary packaging.

Species differences in plasma esterase activity require conservative dose titration, especially in cats and small mammals where published tetracaine pharmacokinetic data are limited. The API should not be assigned a food-producing animal withdrawal interval without species-specific residue studies. If the intended use includes equine or laboratory species, the prescriber must verify current legal status and tolerance data. Compounded preparations should not be mixed with amine-reactive preservatives at high concentration because ionic interactions can reduce antimicrobial activity. Nitrogen sparging of multi-dose vials reduces oxidative degradation, but the headspace oxygen concentration should be measured after filling. Storage below 25 °C in aluminum foil-lined or amber packaging is required; exposure to direct light more than 24 h can produce visible yellowing and related-substance increase above the acceptance threshold. The API is supplied with a retest date, not an expiry date, and the compounder is responsible for assigning finished-product shelf life based on container-closure stability studies.